Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

June 1, 2017

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

temozolomide

standard of care drug

OTHER

3'-deoxy-3'-[18F]fluorothymidine

tracer used for FLT PET CT

OTHER

pharmacological study

DRUG

Mibefradil

Trial Locations (7)

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

21205

Johns Hopkins University, Baltimore

30322

Winship Cancer Institute of Emory University, Atlanta

48202

Henry Ford Hospital, Detroit

35294-3410

UAB Comprehensive Cancer Center, Birmingham

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Cavion, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01480050 - Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma | Biotech Hunter | Biotech Hunter